PDE4 Phase III trial in PF ILD
Research payments
$3,913,882
Through program year 2023, $3,913,882 in research payments was reported against PDE4 Phase III trial in PF ILD, across 240 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $3,760,278 | 160 |
| 2022 | Research | $153,604 | 80 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Curtis Mello North Dartmouth, MA Named on 5 payments
- Alvaro Aranda- Rodriguez Guaynabo, PR Named on 5 payments
- Aaron Milstone Franklin, TN Named on 5 payments
- Marta Kokoszynska Burlington, VT Named on 4 payments
- Gerard Criner Philadelphia, PA Named on 3 payments
- Toby Maher Los Angeles, CA Named on 3 payments
- Daniel Dilling Maywood, IL Named on 3 payments
- Neal Warshoff Loxahatchee, FL Named on 3 payments
- Tejaswini Kulkarni Birmingham, AL Named on 3 payments
- Rafael Martinez Brandon, FL Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.